Cepeginterferon alfa-2b in the treatment of chronic myeloproliferative diseases
Purpose of the study. A comparative evaluation of the effectiveness of different therapeutic strategies in patients with polycythemia vera (PV) and essential thrombocythemia (ET). Materials and methods. Patients with PV or ET, diagnosed according to the criteria WHO 2016 were included in the study....
Main Authors: | A L MELIKYAN, I N SUBORTSEVA, E A GILYAZITDINOVA, T I KOLOSHEJNOVA, E I PUSTOVAYA, E K EGOROVA, A M KOVRIGINA, A B SUDARIKOV, A O ABDULLAEV, E G LOMAIA, N T SIORDIYA, A Yu ZARITSKEY, V G SAVCHENKO |
---|---|
Format: | Article |
Language: | Russian |
Published: |
"Consilium Medicum" Publishing house
2018-07-01
|
Series: | Терапевтический архив |
Subjects: | |
Online Access: | https://ter-arkhiv.ru/0040-3660/article/viewFile/32759/pdf |
Similar Items
-
NEW APPROACHES TO THERAPY OF CLASSICAL PH-NEGATIVE MYELOPROLIFERATIVE DISEASES: THE EXPERIENCE OF EARLY THERAPY WITH CEPEGINTERFERON ALPHA-2B
by: A. S. Polyakov, et al.
Published: (2018-05-01) -
Biology of Myeloproliferative Malignancies
by: AL Melikyan, et al.
Published: (2016-07-01) -
WT1 Gene Overexpression in Differential Diagnosis of Ph-negative Myeloproliferative Disorders
by: EG Lomaia, et al.
Published: (2019-05-01) -
Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV)
by: Lucia Masarova, et al.
Published: (2017-11-01) -
Use of Interferon Alfa in the Treatment of Myeloproliferative Neoplasms: Perspectives and Review of the Literature
by: Joan How, et al.
Published: (2020-07-01)